Drugs cost too much. There is a better way to fund medical innovation

Drugs Medicine 2018 United Nations

UNICEF/Olivier Asselin In Côte d’Ivoire, a counsellor from UNICEF partner NGO Femme Active, instructs an adolescent boy, diagnosed with HIV in 2012, on how to take his antiretroviral (ARV) medication correctly.

This article is brought to you based on the strategic cooperation of The European Sting with the World Economic Forum.

Author: Rufus Pollock, Lead, iMed Project, and Founder and President of Open Knowledge

Drugs are expensive. Very expensive, and becoming ever more so, it seems. Prices for new medicines have been steadily rising for the past few decades. It costs a great deal to bring new drugs to market, the explanation goes, and without high prices, the pipeline of new medicines will run dry.

This argument is unsustainable, especially when even the world’s most developed economies and healthcare systems are struggling to afford vital medicines. To keep paying more for drugs simply cannot be the answer. Bad health affects everyone. We should be urgently seeking new mechanisms of funding medical innovation that do not compromise on access.

There is a strong moral and social obligation for exploring alternatives. Millions of people globally do not have access to the medicines they need to survive. In the US, millions of adults skip prescribed medications due to the high cost. The same is true in Canada, where the public healthcare system does not usually extend to cover prescription medicines, and in Europe, especially in poorer members of the EU.

The situation is worse in less developed countries. Many pay out of pocket for drugs, and the hefty price tags can run many times the annual average income. Two widely used drugs for treating hepatitis C cost the equivalent of one or more years’ average earnings in 12 out of 30 countries, revealed a recent study by the World Health Organization. Millions are dying because they cannot afford the medicine they need to stay alive.

When some members of society lack medicine, there are consequences beyond the individual directly affected. The increased morbidity caused by a lack of access to medication places an extraordinary strain on healthcare systems, exacerbating the drain on their resources from ever more expensive drugs. In addition, unhealthy populations are far less economically productive than healthy ones. Beyond social justice, there are clear economic reasons to find new models of funding medical innovation that do not restrict access to medicine.

The current state of affairs is making the world a more dangerous place. Healthcare systems that are strained by increased morbidity, and by a critical lack of money and medicine, are less likely to be able to contain outbreaks when they occur. Poor global health increases global instability. Failing to ensure everyone has access to necessary medication can have profound knock-on consequences and worsen existing crises.

Moreover, the high sale price of drugs skews incentives for innovation towards wealthy consumers. This means that vital medicines for certain ailments are not accessible when needed on a global scale. For instance, the Ebola virus had been known about for decades before the recent outbreak, and yet virtually no treatments were available. The whole world is unprepared and at risk.

The explanation that pharmaceutical companies offer for high drug prices is compelling. It costs a great deal of money to bring a drug to market, they argue. This is why so many reluctantly accept the current state of affairs, in which innovation justifies restricted access. Though it is true that drugs do cost a lot to bring to market, there is a remarkable lack of consensus on exactly how much.

This is compounded by a systemic lack of transparency. It is often not known how much is spent on what, and how reliant private-sector developments are on publicly funded research. Often, medicines that are developed with significant help from public funds do not reflect that support in prices, and there is no guarantee under the monopoly rights patent system that they should.

Moreover, a great deal of money that could be earmarked for research is spent on marketing instead. Indeed, in some large drug companies, expenditure on marketing outweighs that on research.

This model is unsustainable. So long as we continue to reward innovation through a single channel – buying the drug – access to new medicines will be limited. Ultimately, the problem is about how we pay for medicine. Today, we only pay by purchasing the end product. This means that the costs of manufacture (which is cheap) and innovation (which is expensive) are rolled into one. This puts access and innovation in conflict.

If we were to change how we fund medicines, there could be no conflict. Incentives for innovation and access to affordable drugs could co-exist. We can fund research and production separately. There is no excuse for not exploring the wide systemic changes needed to make that happen.

Today’s model is unsustainable, unhealthy and utterly unnecessary. We can have new medicines and wide access to them. We should be working towards this as a matter of urgency.

And we have ideas. For example, at the iMed Project we’ve been developing innovative two-part payment models for funding medicines that would maintain incentives for innovators while making treatment at cost of manufacture.”











the European Sting Milestones

Featured Stings

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

These are the world’s best cities to be a cyclist

IMF: The global economy keeps growing except Eurozone

Sochi not far away from Ukraine

More women and girls needed in the sciences to solve world’s biggest challenges

Mass-graves found of at least 535 killed during ‘organized and planned’ inter-communal attacks in western DR Congo

MWC 2016 LIVE: Ford trumpets new in-vehicle system, “fundamentally rethinks” transportation

Draghi reveals how failing banks will be dealt, may cut interest rates soon

Chart of the day: These are the cities where the World Cup threatens productivity the most

Solidarity Corps: more opportunities for young people

We are close yet so far…

‘Two pack’ austerity package in force but with less vigor

Is the advent of nationalism to destroy economic neo-liberalism?

Smart city experts should be looking to emerging markets. Here’s why

The Linde Group Logo (Source: The Linde Group website, Press Services, 2018)

EU starts in-depth investigation of Linde-Praxair merger over competition concerns

Draghi to hold on zero interest rates until he leaves ECB

G20 LIVE: G20 Antalya Summit in Numbers, 15-16 November 2015

5 facts about global military spending

An ECB banker wants to change the European social model

EU and Australia launch talks for a broad trade agreement

The results of Finland’s basic income experiment are in. Is it working?

One good reason to feel less blue about the future of our oceans

Fresh airstrikes kill dozens in conflict-ravaged Syria

Countries must up their game to reduce low birth weights, warns UN-backed report

Why EU’s working and unemployed millions remain uncertain or even desperate about their future

The future of work ‘with social justice for all’ tops agenda of centenary UN Labour conference

Rising insecurity in Central Africa Republic threatens wider region, Security Council told

MEPs reject making EU regional funding dependent on economic targets

Realise the beauty of unity in diversity

Energy Union: Commission calls on Member States to step up ambition in plans to implement Paris agreement

Eurozone’s north-south growth gap to become structural

Central African Republic militia leader and football executive, transferred to ICC

The miserables and the untouchables of the economic crisis

TTIP update: postponed vote and INTA meeting shuffle cards again

UN agency warns conditions around Yemen’s key port city of Hudaydah still ‘very bad’, as staff rush to deliver aid

New rules for audiovisual media services approved by Parliament

Draghi repels Trump’s threats, rejects Schauble’s dictums

Chart of the day: This is how many animals we eat each year

‘Path to peace’ on Korean Peninsula only possible through diplomacy and full denuclearization: US tells Security Council

In Tanzania visit, UNHCR official stresses freedom of choice is crucial for refugee returns

‘Chance for peace’ in South Sudan finally within reach, declares UN Peacekeeping chief

How electrification can supercharge the energy transition

Digital Single Market: Cheaper calls to other EU countries as of 15 May

Medicine and mental health: relax, the doctor is a lifelong learner

Commission: Gifts of €6 billion and free trainees to ‘help’ poor employers

Catalan Pro-Independence vote: how many hits can Brussels sustain at the same time?

250 days until the European Parliament elections

‘Great cause of concern’ UN chief tells Security Council, surveying ‘bleak’ state of civilian protection

Political power of women suffering ‘serious regression’, General Assembly President warns

Markets are more sensitive to Greece’s woes than Merkel

Who can compel Wallonia to unlock CETA, the EU-Canada free trade pack?

A day in the life of a refugee: why should we care?

This chart shows the fall in coal-power plants being planned around the world

EU leaders agree on 2030 Climate and Energy Package: is “flexible” brave enough?

These are the 5 most exciting cycling projects in the world

Yanis Varoufakis: “Unsustainable debt turns the creditor into Leviathan; Life under it is becoming nasty, brutish and short”

OECD survey reveals many people unhappy with public services and benefits

The West cannot ignore Russia; dazed Germany sitting on the fence

Juncker Plan reaches almost €410 billion in triggered investment across the EU

Elections in Europe: No risks for the EU, leaders readying to face Trump-Brexit

European Commission adopts new list of third countries with weak anti-money laundering and terrorist financing regimes

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s